1.9308.10% ( -0.170 )
Closed: Nov 12, 16:00:00 (EDT)Valuation
Current ValuationThe current P/E ratio is -0.53, within the reasonable range, cheaper than 42.91% of the time in the past 3 years, and the industry ranks 75/172, the industry Median -0.71.
-0.525xP/E
$2.10Stock price
$-4.00Earnings per share
-0.525xP/E
Stock price$2.10Earnings per share$-4.00
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -0.57x
- Typical range
- -0.89x–-0.36x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
014284256
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
GKOSUSGlaukos | -85.86x | 90.98% | $14.58B |
BAXUSBaxter | -18.85x | 166.27% | $13.63B |
PLSEUSPulse Biosciences | -50.06x | 21.30% | $4.19B |
AXGNUSAxogen | -107.76x | 12.42% | $3.44B |
IRTCUSIRhythm | -75.76x | 16.03% | $2.92B |
ASSTUSStrive | -9.79x | 82.39% | $2.88B |
BFLYUSButterfly Network | -35.57x | 36.13% | $1.91B |
KMTSUSKestra Medical Tech | -12.37x | 0.79% | $1.85B |
ENOVUSEnovis | -3.12x | 99.88% | $1.65B |
NVCRUSNovocure | -11.52x | 13.66% | $1.40B |
PRCTUSPROCEPT BioRobotics | -11.69x | 0.27% | $1.34B |
TNDMUSTandem Diabetes | -26.61x | 79.27% | $1.31B |
DRTSUSAlpha Tau Medical | -13.98x | -- | $1.29B |
ATECUSAlphatec | -13.12x | 51.67% | $1.14B |
SIBNUSSI-BONE | -82.21x | 23.07% | $1.13B |
CBLLUSCeribell | -14.61x | 39.46% | $1.08B |
AORTUSArtivion | -55.61x | 320.41% | $980.67M |
BBNXUSBeta Bionics | -11.65x | 13.23% | $968.28M |
QDELUSQuidelOrtho | -2.21x | 72.55% | $817.18M |
SGHTUSSight Sciences | -21.37x | 25.18% | $606.92M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
